A Retro-Prospective Observational Study of Ibrutinib Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
Latest Information Update: 20 Jan 2023
Price :
$35 *
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms FIRE
- Sponsors Janssen-Cilag
- 13 Dec 2022 Third interim results presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 15 Sep 2022 Status changed from active, no longer recruiting to completed.
- 16 Jun 2022 Planned primary completion date changed from 22 May 2022 to 28 Jul 2022.